Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL465567 | 0.86 | ALDH1A1 (0.48) | ERN1ALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL30831887 | 0.86 | ALDH1A1 (0.48) | ERN1ALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL9246447 | 0.85 | ALDH1A1 (0.43) | ERN1ALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL13101273 | 0.84 | ALDH1A1 (0.46) | ERN1ALDH1A1KDM4ETSHRCYP1A2 | |
| SCHEMBL1001988 | 0.84 | ERN1 (0.48) | ERN1ALDH1A1TSHRCYP1A2KMT2A | |
| SCHEMBL29459689 | 0.84 | ERN1 (0.48) | ERN1ALDH1A1TSHRCYP1A2KMT2A | |
| SCHEMBL2415640 | 0.82 | ERN1 (0.44) | ERN1ALDH1A1KDM4ETSHRCYP1A2 | |
| SCHEMBL11044764 | 0.81 | ALDH1A1 (0.44) | ERN1ALDH1A1KDM4ETSHRCYP1A2 | |
| SCHEMBL31395445 | 0.79 | ERN1 (0.42) | ERN1ALDH1A1KDM4ETSHRCYP1A2 | |
| SCHEMBL31280101 | 0.79 | ALDH1A1 (0.42) | ERN1ALDH1A1KDM4EHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108383858-A | Treat the derivative of the imidazo thiadiazoles and Imidazopyrazines of platelet aggregation | 百时美施贵宝公司 | 2018-08-10 | — | — | CN | disclosed |
| CN-104583218-B | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4(PAR4) inhibitors for the treatment of platelet aggregation | 百时美施贵宝公司 | 2018-04-24 | — | — | CN | disclosed |
| CN-104640869-B | Imidazo thiadiazoles and Imidazopyridazine derivative as proteinase activated receptors 4 (PAR4) inhibitor for treating platelet aggregation | 百时美施贵宝公司 | 2017-12-12 | — | — | CN | disclosed |
| CN-104540835-B | The imidazo thiadiazoles derivative as proteinase activated receptors 4 (PAR4) inhibitor for treating platelet aggregation | 百时美施贵宝公司 | 2017-08-08 | — | — | CN | disclosed |
| US-9242970-B2 | Lactam derivatives useful as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-01-26 | — | — | US | disclosed |
| EP-2638008-B1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-07-01 | — | — | EP | disclosed |
| CN-104411713-A | PAR4 agonist peptides | BRISTOL MYERS SQUIBB CO | 2015-03-11 | — | — | CN | disclosed |
| EP-2638008-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-12 | — | — | US | disclosed |
| WO-2012063207-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | ERN1 3585/4885ALDH1A1 2282/4885KDM4E 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.